Back to News
Market Impact: 0.2
Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Oppenheimer initiated coverage of Vanda Pharmaceuticals (NASDAQGM: VNDA) on September 23, 2026, with an Outperform recommendation. VNDA closed at $5.21 on September 22, ahead of the initiation; the article text does not provide a price target or subsequent market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
VNDA0.45
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- Top Wall Street analysts like these 3 dividend stocks for consistent income
- Crocs evp Rupert Campbell sells $399K of CROX stock
- MercadoLibre's Profits Fall Again. What It Means for Investors